Astrazeneca

FromAstraZeneca ([email protected])
Subject (100)Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
Preheader (100)Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
Typography
Arial
Colors
Text Analysis
Body Words119
Subject Words15
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px690 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeAfternoon

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension